Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on OPTIBIOTIX HEALTH PLC. We currently have 40 research reports from 2 professional analysts.
|24Mar17 17:35||RNS||Holding(s) in Company|
|21Mar17 12:00||RNS||Intention to float SkinBiotherapeutics|
|15Mar17 07:00||RNS||Confirmation of Director appointments to the Board|
|08Mar17 07:00||RNS||European agreement with Sacco Srl|
|01Mar17 07:00||RNS||Launch of products at Vitafoods 2017|
|08Feb17 09:30||RNS||Exercise of Warrants and Issue of Equity|
|26Jan17 14:06||RNS||Result of General Meeting|
Frequency of research reports
Research reports on
OPTIBIOTIX HEALTH PLC
OPTIBIOTIX HEALTH PLC
Go with your gut
24 Jan 17
OptiBiotix is an early-stage, revenue-generating life sciences business with novel IP surrounding the modulation of the human microbiome. Its technology is focused on tackling worldwide health issues (e.g. obesity, diabetes, high cholesterol and microbial infections), exploiting these large market segments via the c.£200bn functional foods market by partnering with food, health, wellbeing and pharmaceutical companies that have established routes to market. With the microbiome fast becoming a rapidly growing area of interest, OptiBiotix is well positioned to be one of the leaders in this field – a lower-risk entry into the microbiome space compared with pharma plays with higher regulatory and development risk profiles.
Interim results lead to upgrades
27 Mar 17
Bioventix reported a strong set of interim results with revenues increasing by 32% (c.12-17% at constant exchange rates (CER)), driven largely by the continued roll-out of its customers’ Vitamin D assay products. This, in turn, led to a 41% increase in pre-tax profits and a 40% increase in adjusted EPS; which is reflective of the operational gearing of the business. We are upgrading our adjusted EPS to 78.7p (+5%) and, consequently, are raising our target price to 1750p. At this price level, the shares would trade on a 22.4x FY 2018 P/E and an EV/EBITDA of 17x. We await confirmation of Siemen’s high sensitivity troponin assay launch, expected in FY 2018.
27 Mar 17
Elecosoft* (ELCO): Steadily building profits (CORP) | Bioventix* (BVXP): Interim results lead to upgrades (CORP) | Hurricane Energy (HUR): Halifax discovery (BUY) | KBT Business Technology* (KBT): interims and contract win (CORP) | Independent Oil & Gas* (IOG): Licence updates (CORP)
28 Mar 17
ClearStar* (CLSU): Building a background for growth (CORP) | Sound Energy (SOU): TE-8 results (HOLD) | LiDCO* (LID): 2017 should be a transformative year (CORP) | Proteome Sciences* (PRM): FY 2016 in line. Moving towards breakeven (CORP) | Fulcrum (FCRM): Significant market potential, rising margins and a strong balance sheet (BUY) | Mortgage Advice Bureau (MAB1): Strong and growing intellectual property (BUY) | 7digital* (7DIG): Open offer result (CORP)
Small Cap Breakfast
28 Mar 17
Path Investments—Publication of prospectus from the Energy Investment Company. Raising £1.4m. Admission due on or around 30 March | Franchise Brands—Schedule 1 detailing £28m reverse takeover of Metro Rod. Admission expected 11 April | Alpha FX Group— Schedule 1 from the foreign exchange provider focused on managing exchange rate risk for UK corporates that trade internationally. Fundraise TBC. Admission expected 7 April. | K3 | Capital Group—Schedule 1 from the Group of business and company sales specialists across business transfer, business brokerage and corporate finance. Admission date and fundraise details TBC. | Integumen— Schedule 1 from the personal health company developing and commercialising technology and products for the human integumentary system. Raising £2.16m at 5p. Expected market cap £8.16m. Admission expected 5 April. Tufton | Oceanic Assets– Offer extended to 9 May to enable investors to complete further due diligence.
N+1 Singer - Morning Song 30-03-2017
30 Mar 17
accesso Technology (ACSO LN) Acquisition | Findel (FDL LN) Update on customer redress programme | Hargreaves Services (HSP LN) Blindwells planning approval | Severfield (SFR LN) Upgrading forecasts and reiterating positive view | Summit Therapeutics (SUMM LN) FY results in line; full 24-week PhaseOut DMD data expected in Q1 ’18 | Tribal Group (TRB LN) 2016 delivered and more; future looking bright
N+1 Singer - Morning Song 28-03-2017
28 Mar 17
A G Barr (BAG LN) Share buybacks the main news around FY17 finals | Churchill China (CHH LN) An excellent set of 2016 results and more upgrades | Ergomed (ERGO LN) FY results show strong Services growth; Phase III Zoptrex® data ahead | Instem (INS LN) Investment to accelerate growth trajectory | Severfield (SFR LN) Strong H2 drives upgrades; CEO temporarily steps down due to ill health | Summit Therapeutics (SUMM LN) Strengthening the data package: planned extension of PhaseOut DMD | T. Clarke (CTO LN) Strong conclusion to FY16, record order book